The
Strategic Planning and Business Development (‘SBD’) division
of Pfizer India pro-actively addresses the unique complexities and challenges
of the Indian market, while keeping in mind the strategic imperatives
set by Pfizer's global leadership. SBD's goal is to bring marketing, medical,
financial and technology skills together to develop new kinds and methods
of business, whether organically or in alliance with complementary participants
in the healthcare sector.
Strategic
Planning
SBD
develops the underlying strategic concepts and co-ordinates the preparation
of the rolling 5-year Strategic Plan on behalf of the India leadership
team.
Over the 2003 and 2004 planning cycles, SBD closely evaluated the changing
economic and regulatory environment and recommended a new long-term strategic
vision for Pfizer's business in India. This initiative was undertaken
with the support, views and guidance of the Asia and India leadership
teams. The Strategic Planning & Business Development group in New
York also partnered with India in this effort. It was concluded that India
should reap benefits from Pfizer's high-end product pipeline through new
launches and high-science therapy shaping. These findings have been accepted
and approved by the senior business leadership in New York and Hong Kong.
With the strategic understanding and thought leadership continuously being
developed and refined, SBD also pro-actively articulates Pfizer India's
perspective to the senior management of Pharmaceuticals, R&D, Animal
Health and Information Technology about business opportunities and issues
in India.
Current projects include new thinking about redefining Pfizer India as
a Healthcare company.
Business
Development
SBD
cultivates selective relationships with complementary players, providers
and payors with a view to develop strategic alliances or deals that strengthen
Pfizer's business.
A significant milestone was achieved through the forging of a local co-promotion
agreement with Sanofi-Synthelabo for Daxid (Sertraline). The strategic
intent behind the deal is to speed up the growth of Daxid sales in India
through Sanofi's access to specialists, even as Pfizer prepares to strengthen
its own capabilities in this therapeutic segment.
Previously,
a major transaction undertaken was the divestment of the $ 5 million Protinex
brand to Danish company EAC, which provided a strong boost to non-operational
income in 2002-2003.
Current projects involve implementation steps that will help streamline
Pfizer’s business structure in line with the new strategic vision.
|
